These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33004536)

  • 21. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
    Roofeh D; Lin CJF; Goldin J; Kim GH; Furst DE; Denton CP; Huang S; Khanna D;
    Arthritis Rheumatol; 2021 Jul; 73(7):1301-1310. PubMed ID: 33538094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
    Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
    Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
    Panopoulos ST; Bournia VK; Trakada G; Giavri I; Kostopoulos C; Sfikakis PP
    Lung; 2013 Oct; 191(5):483-9. PubMed ID: 23925736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
    Kuwana M; Takehara K; Tanaka Y; Yamashita K; Katsumata K; Takata M; Shima Y
    Mod Rheumatol; 2024 Mar; 34(3):530-540. PubMed ID: 37436828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
    Azuma A; Chung L; Behera D; Chung M; Kondoh Y; Ogura T; Okamoto M; Swarnakar R; Zeng X; Zou H; Meng X; Gahlemann M; Alves M; Kuwana M;
    Respir Investig; 2021 Mar; 59(2):252-259. PubMed ID: 33223487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.
    Khanna D; Tashkin DP; Denton CP; Lubell MW; Vazquez-Mateo C; Wax S
    Rheumatology (Oxford); 2019 Apr; 58(4):567-579. PubMed ID: 29893938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
    Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
    J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.
    Yang L; Wang Q; Hou Y; Zhao J; Li M; Xu D; Zeng X
    Clin Rheumatol; 2020 Mar; 39(3):813-821. PubMed ID: 31713733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial.
    Acharya N; Sharma SK; Mishra D; Dhooria S; Dhir V; Jain S
    Rheumatol Int; 2020 May; 40(5):703-710. PubMed ID: 32239322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
    Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
    Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
    Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
    J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.